EDSA vs. NNVC, PIRS, TRAW, TNXP, KPRX, ABVC, PPBT, VAXX, AYTU, and RDHL
Should you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include NanoViricides (NNVC), Pieris Pharmaceuticals (PIRS), Traws Pharma (TRAW), Tonix Pharmaceuticals (TNXP), Kiora Pharmaceuticals (KPRX), ABVC BioPharma (ABVC), Purple Biotech (PPBT), Vaxxinity (VAXX), Aytu BioPharma (AYTU), and RedHill Biopharma (RDHL). These companies are all part of the "pharmaceutical preparations" industry.
NanoViricides (NYSE:NNVC) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, community ranking, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.
10.3% of NanoViricides shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 4.6% of NanoViricides shares are held by insiders. Comparatively, 25.0% of Edesa Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, NanoViricides had 6 more articles in the media than Edesa Biotech. MarketBeat recorded 7 mentions for NanoViricides and 1 mentions for Edesa Biotech. NanoViricides' average media sentiment score of 0.67 beat Edesa Biotech's score of 0.40 indicating that Edesa Biotech is being referred to more favorably in the news media.
NanoViricides has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Edesa Biotech has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500.
Edesa Biotech has a consensus price target of $39.00, indicating a potential upside of 757.14%. Given NanoViricides' higher probable upside, analysts plainly believe Edesa Biotech is more favorable than NanoViricides.
Edesa Biotech's return on equity of -63.97% beat NanoViricides' return on equity.
Edesa Biotech received 25 more outperform votes than NanoViricides when rated by MarketBeat users. Likewise, 75.76% of users gave Edesa Biotech an outperform vote while only 0.00% of users gave NanoViricides an outperform vote.
Summary
Edesa Biotech beats NanoViricides on 7 of the 12 factors compared between the two stocks.
Get Edesa Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edesa Biotech Competitors List
Related Companies and Tools
